O

Onxeo SA
PAR:ALONX

Watchlist Manager
Onxeo SA
PAR:ALONX
Watchlist
Price: 0.272 EUR 0.74% Market Closed
Market Cap: €30.2m

Net Margin

-1 355.6%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 355.6%
=
Net Income
€-19.6m
/
Revenue
€1.4m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 355.6%
=
Net Income
€-19.6m
/
Revenue
€1.4m

Peer Comparison

Country Company Market Cap Net
Margin
FR
Onxeo SA
PAR:ALONX
30.2m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.2B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.8B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.3B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 96% of companies in France
Percentile
4th
Based on 2 398 companies
4th percentile
-1 355.6%
Low
-147 400% — -2.2%
Typical Range
-2.2% — 7.1%
High
7.1% — 14 243.8%
Distribution Statistics
France
Min -147 400%
30th Percentile -2.2%
Median 2.6%
70th Percentile 7.1%
Max 14 243.8%

Onxeo SA
Glance View

Market Cap
30.2m EUR
Industry
Biotechnology

Onxeo SA is a is a clinical-stage biotechnology company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2005-07-12. In July 2014, the Company, as the continuing entity, merged with Topotarget AS creating Onxeo, a company dedicated to orphan oncology diseases. Onxeo aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.

ALONX Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-1 355.6%
=
Net Income
€-19.6m
/
Revenue
€1.4m
What is Onxeo SA's current Net Margin?

The current Net Margin for Onxeo SA is -1 355.6%, which is in line with its 3-year median of -1 355.6%.

How has Net Margin changed over time?

Over the last 3 years, Onxeo SA’s Net Margin has decreased from -550.1% to -1 355.6%. During this period, it reached a low of -1 355.6% on Jan 31, 2023 and a high of 61.3% on Dec 31, 2020.

Back to Top